News Archive

Harwood Private Equity invests in Cyprotex PLC

4 September 2013

Cyprotex is a leading pharmaceutical contract research company.  It is an outsourced provider of in-vitro and in-silico analysis of the activity of pharmaceutical compounds, specialising in Absorption, Distribution, Metabolism and Excretion and toxicity (“ADME-Tox”) testing. 

Harwood Private Equity invested in a convertible and notionally convertible loan note in addition to its 29.9% holding of the ordinary shares of the AIM-listed company.  Harwood has appointed its sector-specialist Operational Adviser, Ian Johnson, as Chairman. Christopher Mills has also joined the board.

Timothy Sturm of Harwood Private Equity, said: “We are pleased to have found a creative way of investing in an excellent company.  We look forward to backing its management team with our capital and influencing the company’s path to its objective of achieving significant growth”.

TeamRock wins award

4 September 2013

TeamRock won an award at the Scottish Business Insider Deals & Dealmakers Awards ceremony held in Glasgow on 4 September. 

Following its purchase of two leading rock music magazines from Future Plc and the development of a digital radio station, TeamRock won ‘Small to Mid-sized Company Deal of the Year’ - the category for a Scottish-based company with a turnover of less than £20 million. TeamRock is headquartered in Glasgow.

Commenting on the award, Timothy Sturm of Harwood Private Equity, said “We’re delighted that our investment in TeamRock has generated this award. Our decision to invest was based on the ground-breaking, market-disruptive nature of TeamRock’s business model and the quality of its management team, with whom we are looking forward to a close and fruitful relationship.”